Israel’s BrainStorm has received FDA approval to use its Nurown stem cells in a Phase 2 trial for the treatment of Multiple Sclerosis (MS). MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.  Nurown is already in a Phase 3 trial for ALS (see here).

https://globenewswire.com/news-release/2018/12/17/1667840/0/en/FDA-Accepts-BrainStorm-s-NurOwn-IND-Application-for-Progressive-Multiple-Sclerosis.html